Well Differentiated Grade 3 Neuroendocrine Tumors of the Digestive Tract: A Narrative Review
出版年份 2020 全文链接
标题
Well Differentiated Grade 3 Neuroendocrine Tumors of the Digestive Tract: A Narrative Review
作者
关键词
-
出版物
Journal of Clinical Medicine
Volume 9, Issue 6, Pages 1677
出版商
MDPI AG
发表日期
2020-06-02
DOI
10.3390/jcm9061677
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Pancreatic grade 3 neuroendocrine tumors behave similarly to neuroendocrine carcinomas following resection: a multi-center, international appraisal of the WHO 2010 and WHO 2017 staging schema for pancreatic neuroendocrine lesions
- (2020) Patrick J. Worth et al. HPB
- State of the Art: Evaluating the Role of Theranostics in G3 Neuroendocrine Neoplasms
- (2019) Naj L. Waseem et al. JOURNAL OF NUCLEAR MEDICINE
- Well-differentiated grade 3 neuroendocrine tumours and poorly differentiated grade 3 neuroendocrine carcinomas
- (2019) Sandip Basu et al. NUCLEAR MEDICINE COMMUNICATIONS
- Phase I Trial of Well-Differentiated Neuroendocrine Tumors (NETs) with Radiolabeled Somatostatin Antagonist 177 Lu-Satoreotide Tetraxetan
- (2019) Diane Reidy-Lagunes et al. CLINICAL CANCER RESEARCH
- Chemotherapy in resected neuroendocrine carcinomas of the digestive tract: a national study from the French Group of Endocrine Tumours (GTE)
- (2019) Anna Pellat et al. NEUROENDOCRINOLOGY
- PRRT in high-grade gastroenteropancreatic neuroendocrine neoplasms (WHO G3)
- (2019) Halfdan Sorbye et al. ENDOCRINE-RELATED CANCER
- Well differentiated grade 3 pancreatic neuroendocrine tumors compared with related neoplasms: A morphologic study
- (2018) Carlie S. Sigel et al. CANCER CYTOPATHOLOGY
- Clinical and Biomarker Evaluations of Sunitinib in Patients with Grade 3 Digestive Neuroendocrine Neoplasms
- (2018) Anna Pellat et al. NEUROENDOCRINOLOGY
- Immune Checkpoint Inhibitors in the Treatment of Patients with Neuroendocrine Neoplasia
- (2018) Matthias M. Weber et al. Oncology Research and Treatment
- A randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors: A trial of the ECOG-ACRIN Cancer Research Group (E2211).
- (2018) Pamela L. Kunz et al. JOURNAL OF CLINICAL ONCOLOGY
- Unmet Needs in Functional and Nonfunctional Pancreatic Neuroendocrine Neoplasms
- (2018) Robert T. Jensen et al. NEUROENDOCRINOLOGY
- Poorly differentiated gastro-entero-pancreatic neuroendocrine carcinomas: Are they really heterogeneous? Insights from the FFCD-GTE national cohort
- (2017) T. Walter et al. EUROPEAN JOURNAL OF CANCER
- Whole-genome landscape of pancreatic neuroendocrine tumours
- (2017) Aldo Scarpa et al. NATURE
- Digestive System Mixed Neuroendocrine-Non-Neuroendocrine Neoplasms
- (2017) Louis de Mestier et al. NEUROENDOCRINOLOGY
- ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Pathology - Diagnosis and Prognostic Stratification
- (2017) Aurel Perren et al. NEUROENDOCRINOLOGY
- Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors
- (2017) Jonathan Strosberg et al. NEW ENGLAND JOURNAL OF MEDICINE
- Everolimus in Pancreatic Neuroendocrine Carcinomas G3
- (2017) Francesco Panzuto et al. PANCREAS
- Prise en charge thérapeutique des tumeurs neuroendocrines peu différenciées pulmonaires et des carcinomes neuroendocrines digestifs
- (2016) Anna Pellat et al. BULLETIN DU CANCER
- Heterogeneity of grade 3 gastroenteropancreatic neuroendocrine carcinomas: New insights and treatment implications
- (2016) Nicola Fazio et al. CANCER TREATMENT REVIEWS
- Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study
- (2016) James C Yao et al. LANCET
- Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial
- (2016) Howard L Kaufman et al. LANCET ONCOLOGY
- Professional Practices and Diagnostic Issues in Neuroendocrine Tumour Pathology: Results of a Prospective One-Year Survey among French Pathologists (the PRONET Study)
- (2016) Jean-Yves Scoazec et al. NEUROENDOCRINOLOGY
- ENETS 2016 Consensus Guidelines for the Management of Patients with Digestive Neuroendocrine Tumors: An Update
- (2016) Dermot O'Toole et al. NEUROENDOCRINOLOGY
- PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma
- (2016) Paul T. Nghiem et al. NEW ENGLAND JOURNAL OF MEDICINE
- Gastroenteropancreatic Well-Differentiated Grade 3 Neuroendocrine Tumors: Review and Position Statement
- (2016) Romain Coriat et al. ONCOLOGIST
- The High-grade (WHO G3) Pancreatic Neuroendocrine Tumor Category Is Morphologically and Biologically Heterogenous and Includes Both Well Differentiated and Poorly Differentiated Neoplasms
- (2015) Olca Basturk et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Surgical Treatment as a Principle for Patients with High-Grade Pancreatic Neuroendocrine Carcinoma: A Nordic Multicenter Comparative Study
- (2015) Sven-Petter Haugvik et al. ANNALS OF SURGICAL ONCOLOGY
- Gemcitabine and oxaliplatin or alkylating agents for neuroendocrine tumors: Comparison of efficacy and search for predictive factors guiding treatment choice
- (2015) Anne-Sophie Dussol et al. CANCER
- Survival of Patients With Neuroendocrine Carcinoma of the Colon and Rectum
- (2015) Hammad Shafqat et al. DISEASES OF THE COLON & RECTUM
- Post-first-line FOLFOX chemotherapy for grade 3 neuroendocrine carcinoma
- (2015) J. Hadoux et al. ENDOCRINE-RELATED CANCER
- Characteristics and treatment of patients with G3 gastroenteropancreatic neuroendocrine neoplasms
- (2015) M Heetfeld et al. ENDOCRINE-RELATED CANCER
- A Retrospective Review of 126 High-Grade Neuroendocrine Carcinomas of the Colon and Rectum
- (2014) James D. Smith et al. ANNALS OF SURGICAL ONCOLOGY
- Bevacizumab combined with 5-FU/streptozocin in patients with progressive metastatic well-differentiated pancreatic endocrine tumours (BETTER trial) – A phase II non-randomised trial
- (2014) Michel Ducreux et al. EUROPEAN JOURNAL OF CANCER
- Bevacizumab plus capecitabine in patients with progressive advanced well-differentiated neuroendocrine tumors of the gastro-intestinal (GI-NETs) tract (BETTER trial) – A phase II non-randomised trial
- (2014) Emmanuel Mitry et al. EUROPEAN JOURNAL OF CANCER
- Calculation of the Ki67 index in pancreatic neuroendocrine tumors: a comparative analysis of four counting methodologies
- (2014) Michelle D Reid et al. MODERN PATHOLOGY
- Grading of Neuroendocrine Neoplasms: Mitoses and Ki-67 Are Both Essential
- (2014) Marie-Louise F. van Velthuysen et al. NEUROENDOCRINOLOGY
- Reliability of Proliferation Assessment by Ki-67 Expression in Neuroendocrine Neoplasms: Eyeballing or Image Analysis?
- (2014) Marie-Louise F. van Velthuysen et al. NEUROENDOCRINOLOGY
- Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors
- (2014) Martyn E. Caplin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pancreatic neuroendocrine tumour grading on endoscopic ultrasound-guided fine needle aspiration: high reproducibility and inter-observer agreement of the Ki-67 labelling index
- (2013) B. Weynand et al. CYTOPATHOLOGY
- Are G3 ENETS neuroendocrine neoplasms heterogeneous?
- (2013) Fritz-Line Vélayoudom-Céphise et al. ENDOCRINE-RELATED CANCER
- Incidence and survival of neuroendocrine tumours in the Netherlands according to histological grade: Experience of two decades of cancer registry
- (2013) Catharina M. Korse et al. EUROPEAN JOURNAL OF CANCER
- Small Cell and Large Cell Neuroendocrine Carcinomas of the Pancreas are Genetically Similar and Distinct From Well-differentiated Pancreatic Neuroendocrine Tumors
- (2012) Shinichi Yachida et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Objective Quantification of the Ki67 Proliferative Index in Neuroendocrine Tumors of the Gastroenteropancreatic System
- (2012) Laura H. Tang et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): The NORDIC NEC study
- (2012) H. Sorbye et al. ANNALS OF ONCOLOGY
- FOLFIRI regimen: an effective second-line chemotherapy after failure of etoposide–platinum combination in patients with neuroendocrine carcinomas grade 3
- (2012) O Hentic et al. ENDOCRINE-RELATED CANCER
- Ki67 proliferation index, hepatic tumor load, and pretreatment tumor growth predict the antitumoral efficacy of lanreotide in patients with malignant digestive neuroendocrine tumors
- (2012) Maxime Palazzo et al. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
- Feasibility and Efficacy of Combined Cisplatin and Irinotecan Chemotherapy for Poorly Differentiated Neuroendocrine Carcinomas
- (2012) K. Nakano et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- ENETS Consensus Guidelines for the Management of Patients with Digestive Neuroendocrine Neoplasms of the Digestive System: Well-Differentiated Pancreatic Non-Functioning Tumors
- (2012) Massimo Falconi et al. NEUROENDOCRINOLOGY
- ENETS Consensus Guidelines for the Management of Patients with Neuroendocrine Neoplasms from the Jejuno-Ileum and the Appendix Including Goblet Cell Carcinomas
- (2012) Ulrich-Frank Pape et al. NEUROENDOCRINOLOGY
- ENETS Consensus Guidelines for the Management of Patients with Liver and Other Distant Metastases from Neuroendocrine Neoplasms of Foregut, Midgut, Hindgut, and Unknown Primary
- (2012) Marianne Pavel et al. NEUROENDOCRINOLOGY
- Liver-directed therapies in liver metastases from neuroendocrine tumors of the gastrointestinal tract
- (2012) Magaly Zappa et al. Targeted Oncology
- Clinical effect of temozolomide-based chemotherapy in poorly differentiated endocrine carcinoma after progression on first-line chemotherapy
- (2011) Staffan Welin et al. CANCER
- Phase II study of first-line FOLFIRI for progressive metastatic well-differentiated pancreatic endocrine carcinoma
- (2011) Hedia Brixi-Benmansour et al. DIGESTIVE AND LIVER DISEASE
- Prognostic Validity of a Novel American Joint Committee on Cancer Staging Classification for Pancreatic Neuroendocrine Tumors
- (2011) Jonathan R. Strosberg et al. JOURNAL OF CLINICAL ONCOLOGY
- Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study
- (2011) Marianne E Pavel et al. LANCET
- Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors
- (2011) Eric Raymond et al. NEW ENGLAND JOURNAL OF MEDICINE
- Everolimus for Advanced Pancreatic Neuroendocrine Tumors
- (2011) James C. Yao et al. NEW ENGLAND JOURNAL OF MEDICINE
- DAXX/ATRX, MEN1, and mTOR Pathway Genes Are Frequently Altered in Pancreatic Neuroendocrine Tumors
- (2011) Y. Jiao et al. SCIENCE
- First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas
- (2010) Jonathan R. Strosberg et al. CANCER
- 18F-Fluorodeoxyglucose Positron Emission Tomography Predicts Survival of Patients with Neuroendocrine Tumors
- (2010) T. Binderup et al. CLINICAL CANCER RESEARCH
- Gastroenteropancreatic neuroendocrine tumours: the current incidence and staging based on the WHO and European Neuroendocrine Tumour Society classification: an analysis based on prospectively collected parameters
- (2010) Martin B Niederle et al. ENDOCRINE-RELATED CANCER
- Functional Imaging of Neuroendocrine Tumors: A Head-to-Head Comparison of Somatostatin Receptor Scintigraphy, 123I-MIBG Scintigraphy, and 18F-FDG PET
- (2010) T. Binderup et al. JOURNAL OF NUCLEAR MEDICINE
- NANETS Treatment Guidelines
- (2010) Matthew H. Kulke et al. PANCREAS
- The NANETS Consensus Guideline for the Diagnosis and Management of Neuroendocrine Tumors
- (2010) J. Philip Boudreaux et al. PANCREAS
- The NANETS Consensus Guidelines for the Diagnosis and Management of Poorly Differentiated (High-Grade) Extrapulmonary Neuroendocrine Carcinomas
- (2010) Jonathan R. Strosberg et al. PANCREAS
- Gemcitabine and oxaliplatin combination chemotherapy for metastatic well-differentiated neuroendocrine carcinomas
- (2009) Philippe A. Cassier et al. CANCER
- Phase III trial of chemotherapy using 5-fluorouracil and streptozotocin compared with interferon α for advanced carcinoid tumors: FNCLCC–FFCD 9710
- (2009) Laetitia Dahan et al. ENDOCRINE-RELATED CANCER
- Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors: A Report From the PROMID Study Group
- (2009) Anja Rinke et al. JOURNAL OF CLINICAL ONCOLOGY
- One Hundred Years After “Carcinoid”: Epidemiology of and Prognostic Factors for Neuroendocrine Tumors in 35,825 Cases in the United States
- (2008) James C. Yao et al. JOURNAL OF CLINICAL ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now